Ulcerative colitis K51
Conditions
Interventions
Group 1: Patients with mild to moderate ulcerative colitis (UC) and an acute UC-flare, as assessed by the physician, are included. Patients will start treatment with the mesalazine 1600 mg tablet (ASA
Sponsors
Tillotts Pharma GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients - Who are at least 18 years of age at study inclusion - with mild to moderate ulcerative colitis as assessed by the physician - with an acute ulcerative colitis flare as assessed by the physician - in whom treatment with mesalazine 1600 mg tablet is planned
Exclusion criteria
Exclusion criteria: Patients with severe ulcerative colitis as assessed by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collection of real-life data on the dosing behavior of mesalazine: description of the use of mesalazine in treatment reality in patients under therapy with the mesalazine tablet with the currently highest available active strength (1600 mg active ingredient per tablet). | — |
Secondary
| Measure | Time frame |
|---|---|
| Description of: - Adherence of patients with ulcerative colitis to the mesalazine 1600 mg tablet at week 8 and week 14 after an acute flare - Clinical remission/response at week 8 and week 14 - Association between degree of adherence and remission - Correlation between fecal calprotectin (optional for patients, collected only if part of routine care) and Partial Mayo Score - Adherence of patients to previous mesalazine-therapy (for patients who switched from another mesalazine preparation to the mesalazine 1600 mg tablet) - Patient preference for a particular mesalazine-therapy (in patients who have been switched from another oral mesalazine preparation to the mesalazine 1600 mg tablet). | — |
Countries
Germany
Contacts
Public ContactMichelle Rothaug
CED Service GmbH
Outcome results
None listed